word count: 244 20 Manuscript word count: 8492 ABSTRACT 35 Hepatitis C virus (HCV) represents a major global health problem for which a vaccine is 36 not available. MVA-HCV is a unique HCV vaccine candidate based in the modified 37 vaccinia virus Ankara (MVA) vector expressing the nearly full-length genome of HCV 38 genotype 1a that elicits broad and polyfunctional CD8 + T-cell responses in mice. With the 39 aim to improve the immune response of MVA-HCV and due to the importance of 40 interferon (IFN) in HCV infection, we deleted in MVA-HCV the vaccinia virus (VACV) 41 C6L gene, encoding an inhibitor of IFN-β that prevents activation of the transcription 42 factors IRF3 and IRF7. The resulting vaccine candidate (MVA-HCV ΔC6L) expresses all 43 HCV antigens and deletion of C6L had no effect on viral growth in permissive chicken 44 cells. In human monocyte-derived dendritic cells, infection with MVA-HCV ΔC6L 45 triggered severe down-regulation of IFN-β, IFN-β-induced genes and cytokines similarly 46 to MVA-HCV, as defined by real-time PCR and microarray analysis. In infected mice both 47 vectors had a similar profile of recruited immune cells and induced comparable levels of 48
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bars). In the case of cells infected with MVA-HCV or MVA-HCV ∆C6L host gene 205 expression was still upregulated but reduced several-fold in most of the genes when 206 compared to MVA-WT (Fig. 3A , grey and white bars); and only one gene (TFEB) was 207 downregulated by the three vectors (Fig. 3A) . Genes significantly downregulated in HCV and MVA-HCV ∆C6L compared to MVA-WT include IFN-related genes (OASL, 209 ZC3HAV1, IFN-B1, IFIT1, IFIT2 and IFIT3), genes involved in apoptosis (PMAIP1) and 210 histones (HIST1H4D, HIST1H4F, HIST1H4K, HIST2H4B, HIST1H4H and HIST1H4J). 211 Additionally, in Table 1 we show the host genes that were found differentially expressed in 212 MVA-HCV ∆C6L compared to MVA-HCV, with most of the genes downregulated by 213 MVA-HCV ∆C6L in comparison to MVA-HCV. 214 To validate the microarray results, we performed real-time PCR of the mRNA 215 samples using specific primers for three representative host genes (IFN-β, IFIT1 and IFIT 216 2) (Fig. 3B ). The results obtained were in accordance with the microarray data, showing a 217 downregulation of these genes in MVA-HCV and MVA-HCV ΔC6L, compared to WT in the three human donor samples. 219 These results established that in moDCs infected with MVA-HCV and MVA-HCV 220 ΔC6L there is a reduced host gene expression compared to parental MVA-WT, with minor 221 differences in extent between the two recombinant viruses. and CD8 + T cells) than for MVA-WT at 24 h post inoculation ( Fig. 4 and Table 2 ). At 24 h the neutrophils recruited with the MVA vectors were neutrophils α. There were no 239 significant differences between MVA-HCV and MVA-HCV ΔC6L at any time point, with 240 only a trend to higher number of recruited NK, NKT cells and neutrophils (total, α and β) 241 in the case of MVA-HCV ΔC6L at 48 h. This tendency is statistically significant in the 242 number of neutrophils recruited (total, α and β) in the comparison of MVA-HCV ΔC6L 243 with MVA-WT (Table 2) . 244 These results showed the impact of the MVA vectors on immune cell recruitment in 245 the peritoneal cavity of mice during virus infection, revealing statistical differences in 246 some innate cell recruitment between them. antibodies to identify T cell populations (CD4 and CD8) and responding cells (CD107a on 260 the surface of activated T cells as an indirect marker of cytotoxicity, and production of 261 IFN-γ, TNF-α, and IL-2 cytokines).
262
The magnitude of the total HCV-specific CD8 + T cell adaptive immune responses 263 (determined as the sum of cells producing IFN-γ, TNF-α, and/or IL-2, as well as the 264 expression of CD107a degranulation marker) obtained for all the HCV peptide pools (Core 265 + E1 + E2 + p7+NS2 + NS3 + NS4 + NS5) was high and similar in mice immunized with 266 MVA-HCV and MVA-HCV ΔC6L. The immune response was largely mediated by HCV-267 specific CD8 + T cells, while levels of HCV-specific CD4 + T cells were very low (Fig. 5A; 268 and data not shown).
269
The profile of HCV-specific CD8 + T cell adaptive immune responses elicited by 270 MVA-HCV and MVA-HCV ΔC6L immunization groups showed that the response was 271 directed preferentially against p7+NS2 and to a lesser extent toward NS3 in both 272 immunization groups (Fig. 5B ). Interestingly, MVA-HCV induced significantly higher 273 p7+NS2-specific CD8 + T cell immune responses than MVA-HCV ΔC6L, while MVA-274 HCV ΔC6L elicited higher NS3-specific CD8 + T cell immune responses than MVA-HCV 275 ( Fig. 5B ).
276
The quality of the HCV-specific CD8 + T cell immune responses was analyzed 277 measuring the pattern of cytokine production (IFN-γ, TNF-α, and/or IL-2) and/or its 278 cytotoxic potential (CD107a degranulation). As shown in Fig. 5C (pie charts), HCV-279 specific CD8 + T cell immune responses were similar and highly polyfunctional in animals 280 immunized with MVA-HCV and MVA-HCV ΔC6L, with around 60% and 5% of the 281 CD8 + T cells having three and four functions, respectively. HCV-specific CD8 + T cells 282 producing CD107a + IFN-γ + TNF-α, IFN-γ + TNF-α + IL-2 or IFN-γ + TNF-α were the 283 most abundant cell populations induced by MVA-HCV and MVA-HCV ΔC6L, which 284 were of a similar magnitude between both immunization groups ( Fig. 5C , bars).
285
These results indicate that there are no significant differences in the magnitude and 286 quality of the total HCV-specific CD8 + T cell adaptive immune responses induced by 287 MVA-HCV and MVA-HCV ΔC6L. However, the pattern of response was different; with 288 MVA-HCV inducing higher p7+NS2-specific CD8 + T cell responses than MVA-HCV 289 ΔC6L and MVA-HCV ΔC6L eliciting higher NS3-specific CD8 + T cell immune responses 290 than MVA-HCV.
291

MVA-HCV and MVA-HCV ΔC6L induced T cell memory immune responses.
292
It has been reported that memory CD8 + T cells are required for protection from persistent 293 HCV (27). Thus, to study the HCV-specific T cell memory immune responses induced by 294 MVA-HCV and MVA-HCV ΔC6L, four mice of each immunization group were sacrificed 295 53 days after the second immunization and pools of splenocytes from each group were 296 stimulated ex vivo with a panel of HCV peptides, similarly to the adaptive immune 297 response protocol described above and in Materials and Methods.
298
The magnitude of the total HCV-specific CD8 + T cell memory immune responses 299 were high and similar in mice immunized with MVA-HCV and MVA-HCV ΔC6L; with 300 the HCV-specific T cell memory immune responses largely mediated by CD8 + T cells, 301 with very low HCV-specific CD4 + T cells ( Fig. 6A ; and data not shown). Moreover, as in 302 adaptive phase, the pattern of HCV-specific CD8 + T cell memory immune responses 303 induced by MVA-HCV and MVA-HCV ΔC6L showed that in both groups the response 304 was mainly directed against p7+NS2 and then towards NS3 (Fig. 6B ). MVA-HCV elicited 305 significantly higher p7+NS2-specific CD8 + T cell immune responses than MVA-HCV 306 ΔC6L, and MVA-HCV ΔC6L elicited higher NS3-specific CD8 + T cell immune responses 307 than MVA-HCV ( Fig. 6B ).
308
The quality of the HCV-specific CD8 + T cell memory immune responses showed 309 that MVA-HCV and MVA-HCV ΔC6L triggered highly polyfunctional HCV-specific 310 CD8 + T cells, with around 65% and 23% of the CD8 + T cells having three and four has been controversial for many years, it has been described that passive transfer of anti-E2 331 antibodies protects against infection in chimpanzees and chimeric mice (28-30). Thus, we 332 analyzed the humoral immune responses induced after immunization with MVA-HCV and 333 MVA-HCV ΔC6L, quantifying by enzyme-linked immunosorbent assay (ELISA) the total 334 IgG levels of antibodies against HCV E2 protein (strain H77) in sera obtained from 335 individual mice 10 days post-boost ( Fig. 7) . The results showed that both immunization 336 groups were able to elicit antibodies against E2 in the adaptive phase. however, due to the anti-adeno sero-prevalence in human population and the cross-reactive 369 immunity between both vectors (AdCh3NSmut and Ad6NSmut), the immunogenicity was 370 improved when MVA was administered as a boost (33). Moreover, a recent study showed 371 that in immunized mice an MVA vector expressing NS3/4A is superior to adenovirus-5 372 vector in the induction of CD8 + T cell memory responses against HCV (35). 373 We have previously described an MVA-based vaccine candidate for HCV (termed 374 MVA-HCV) that expresses most of the HCV genome (Core, E1, E2, p7, NS2, NS3, NS4a, 375 NS4b, NS5a and part of NS5b protein) (26). MVA-HCV elicited polyfunctional T cell 376 responses with memory phenotype in wild-type and humanized mice, being the first 377 vaccine candidate encoding all HCV proteins (structural and nonstructural) and therefore 378 covering most of the T and B cell determinants described for HCV. However, efforts to 379 understand the HCV-specific immune responses elicited by MVA-HCV are needed in 380 order to improve this vaccine candidate. Firstly, despite of its attenuated phenotype, MVA 381 still encodes for proteins that can interfere with host immune responses to viral infection 382 (36-38), and it is described that deletion of VACV immunomodulatory genes can enhance 383 its immunogenicity (20). Secondly, IFN-based therapy in combination with ribavirin has 384 been the treatment of first choice despite its well-known side effects, and even in the era of HCV-specific CD8 + T memory cells, with a predominance of TEM phenotype, which has 473 been described to be required to eliminate the virus through the production of cytolytic 474 molecules and cytokines (62).
475
To boost efficacy of an HCV vaccine candidate, it should be combined T and B cell 476 responses in a synergistic effect (31), since there is rising evidence that antibodies can be 477 necessary to control HCV replication, especially in early stages of infection (1, 12) . A 478 meta-analysis study showed that the inclusion of envelope proteins in a vaccine and 479 therefore the presence of antibodies indicate higher chances of resolving infection in 480 chimpanzees, suggesting that neutralizing antibodies (NAbs) can play a role in protection 481 (8). HCV E2 glycoprotein contains the receptor binding domain and is the major target for 482 Nabs, which interfere with virion's attachment to cells (63). MVA-HCV and MVA-HCV 483 ∆C6L were able to elicit antibodies against E2 protein in immunized mice, indicating that (see later). Virus infections in cells were performed as previously described (64, 65). All 535 viruses were grown in primary CEF cells, purified by centrifugation through two 36% 536 sucrose cushions in 10 mM Tris-HCl (pH 9) and titrated at least two times in DF-1 cells by 537 plaque immunostaining assay, using rabbit polyclonal antibody against VACV strain 538 Western reserve (WR) (Centro Nacional de Biotecnología; diluted 1:1000), followed by an 539 anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody (Sigma-Aldrich; 540 diluted 1:1,000), as previously described (66). All viruses were not contaminated with analysis. Thus, viral DNA was extracted from DF-1 cells mock infected or infected at 5 563 PFU/cell with MVA-WT, MVA-HCV or MVA-HCV ΔC6L, as previously described (26).
564
To verify that deletion of the VACV C6L gene was correctly present, primers RFC6L-565 AatII-F and LFC6L-BamHI-R (previously described in (22) Thermofisher; diluted 1:5,000), mouse monoclonal antibodies against E1 (Acris 582 Antibodies; diluted 1:1,000), E2 (GenWay Biotech; diluted 1:1,000), and NS5A (GenWay 583 Biotech; diluted 1:1,000) or goat polyclonal antibody against NS3 (Abcam; diluted 1:500), 584 to evaluate the expression of the different HCV proteins. As loading controls, we used 585 rabbit anti-β-actin (Cell Signaling; diluted 1:1,000), and rabbit anti-VACV E3 (Centro Differentially expressed genes in microarray analysis were selected after application of the 740 following statistical filters (FDR Prod P value <0.05 or P value LIMMA < 0.05 and fold 741 change ≥ 2 or ≤ -2). The statistical significance of differences between groups in the 742 experiment of cell recruitment was determined by Student's t test (unpaired, two tailed).
743
Statistical analysis of the ICS data was realized as previously described (67, 75) using an 744 approach that corrects measurements for the negative-control medium response (RPMI), groups was calculated with a t-student test (unpaired, non-parametric, two tails). P values 807 are indicated in Table 2 . in comparison with MVA-HCV. a The gene name and the probe ID are indicated. b Differentially expressed genes were evaluated by the non-parametric algorithm 'Rank Products' available as "RankProd" package at Bioconductor, and the genes were filtered using a P value Limma <0.05 and a fold change ≥ 2 or ≤ -2.
